Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5

Fig. 1

The growth of three different established patient-derived xenografts is inhibited by treatment with drozitumab. SCID mice implanted with tumors a) 11424 and b) 14244 were given weekly intraperitoneal injections of drozitumab. c) Mice with xenograft 12424 were given drozitumab daily by intraperitoneal injection. n = 5–9 mice/group. Statistics by 2-way Anova and Bonferroni post-test; ****p <0.0001

Back to article page